

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

**IN RE: OZEMPIC (SEMAGLUTIDE)
PATENT LITIGATION**

No. 22-md-3038-CFC

**NOVO NORDISK INC. and NOVO
NORDISK A/S,**

No. 22-cv-294-CFC
CONSOLIDATED
ANDA CASE

Plaintiffs/Counterclaim
Defendants,

v.

RIO BIOPHARMACEUTICALS INC. et al.,

Defendants/Counterclaim
Plaintiffs.

**NOVO NORDISK INC. and NOVO
NORDISK A/S,**

No. 22-cv-1040-CFC
ANDA CASE

Plaintiffs/Counterclaim
Defendants,

v.

MYLAN PHARMACEUTICALS INC.,

Defendant/Counterclaim
Plaintiff.

**Opening Expert Report of Dr. John Bantle
Regarding Invalidity of U.S. Patent No. 10,335,462**

TABLE OF CONTENTS

	Page
I. Qualifications and Background.....	1
A. Education and Experience; Prior Testimony	1
B. Basis for Opinions and Materials Considered	4
C. Retention and Compensation	4
II. Summary of Opinions	4
III. Legal Standards	7
IV. Person of Ordinary Skill in the Art.....	9
V. The '462 Patent and Its Asserted Claims	11
VI. Claim Construction.....	19
VII. Background on Diabetes and the use of GLP-1 Derivatives for the Treatment of Diabetes.....	20
A. Diabetes Generally	20
B. Diabetes Treatment.....	22
C. The Use of GLP-1 Derivatives to Treat Diabetes.....	25
D. Use of Liraglutide to Treat Diabetes	27
E. Extended-Use GLP-1 Receptor Agonists	32
VIII. Scope and Content of the Prior Art	41
A. Lovshin.....	43
B. Madsbad	45
C. U.S. Patent No. 8,114,833.....	47
D. WO 2006/097537	54
E. WO 2011/138421	60
F. NCT00696657 Semaglutide Clinical Trial Record	64
1. Clinical Trial No. NCT00696657	64
2. ClinicalTrials.gov is a Part of the POSA's Knowledge	66
G. Other Technical Background Forming the POSA's Knowledge	73

TABLE OF CONTENTS

(continued)

	Page
1. Clinical Trial No. NCT00851773	73
2. Bhansali	79
3. Drucker 2003.....	84
4. Holst 2004.....	85
5. Knudsen 2001	89
6. Knudsen 2004	93
7. Knudsen patent (U.S. Patent No. 6,268,343).....	98
8. Lund.....	103
9. U.S. Patent Application Pub. No. US2007/0010424	103
10. Victoza label.....	108
11. WO 03/002136	111
12. Additional prior art and references	116
IX. Invalidity of the Asserted Claims of the '462 Patent.....	117
A. Each of WO '421, NCT00696657, and Lovshin anticipated claims 1 and 3.....	117
1. WO '421	118
2. NCT00696657	126
3. Lovshin.....	133
B. All Asserted Claims of the '462 Patent Would Have Been Obvious Over the Prior Art	141
1. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '421, NCT00696657, WO '537 and/or Lovshin, optionally in view of one or more of the '833 Patent and Madsbad	142
2. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '421 alone or in view of the '833 patent	168
3. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '537 in view of Lovshin	181

TABLE OF CONTENTS
(continued)

	Page
C. All Claims of the '462 Patent Are Invalid for Lack of Written Description if They Would not have been Obvious	194
X. Reservation of Rights	202

TABLE OF ABBREVIATIONS

Full Name of Cited Reference	Abbreviation
U.S. Patent Application Pub. No. US2011/0166321	'321 publication
U.S. Patent Application Pub. No. US2007/0010424	'424 publication
U.S. Patent No. 10,335,462 NN-OZEM-000000071-95	'462 patent
U.S. Patent No. 10,335,462 file history NN-OZEM-000003820-4446	'462 file history
U.S. Patent No. 5,512,549	'549 patent
U.S. Patent No. 8,114,833 SEMA(JDG)_0000447-468	'833 patent
Banting, <i>The Internal Secretion of the Pancreas</i> , 7 J. LAB. CLINICAL MED. 251 (1922)	Banting
Bell, <i>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides</i> , 302 NATURE 716 (1983)	Bell
Bhansali, <i>Historical Overview of Incretin Based Therapies</i> , 58 J. ASSOC. OF PHYSICIANS OF INDIA 10 (2010) SEMA(JDG)_0000014-18	Bhansali
Highlights of Prescribing Information: Bydureon, Rev. 1/2012 https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200Orig1s0001bledt.pdf (last accessed Feb. 26, 2024)	Bydureon label
Highlights of Prescribing Information: Byetta, Rev. 10/2009 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s251bl.pdf (last accessed Feb. 26, 2024)	Byetta label
<i>ClinicalTrials.gov Background</i> , CLINICALTRIALS.GOV, https://clinicaltrials.gov/about-site/about-ctg (last visited Mar. 15, 2024)	ClinicalTrials.gov Background

TABLE OF ABBREVIATIONS
(continued)

Full Name of Cited Reference	Abbreviation
Drab, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects</i> , 30 PHARMACOTHERAPY 609 (2010)	Drab
Drucker, <i>Enhancing Incretin Action for the Treatment of Type 2 Diabetes</i> , 26 DIABETES CARE 2929 (2003)	Drucker 2003
Drucker, <i>The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes</i> , 368 LANCET 1696 (2006)	Drucker 2006a
Drucker, <i>The Biology Of Incretin Hormones</i> , 3 CELL METABOLISM 153 (2006)	Drucker 2006b
Glaesner, <i>Engineering and Characterization of the Long-Acting Glucagon-Like Peptide-1 Analogue LY2189265, an Fc Fusion Protein</i> , 26 DIABETES/METABOLISM RSCH. & REV. 287 (2010)	Glaesner
HARRISON'S PRINCIPLES OF INTERNAL MED., Chapter 338 (Fauci et al. eds. 17th ed. 2008)	Harrison's
<i>Award: ClinicalTrials.gov</i> , https://ash.harvard.edu/news/clinicaltrials.gov (last visited Mar. 15, 2024)	Harvard Award
Holst, <i>Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from the Distal Gut</i> , 211 FEBS LETTERS 169 (1987)	Holst 1987
Holst, <i>Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Type 2 Diabetes Mellitus</i> , 4 CURRENT OP. IN PHARMACOLOGY 589 (2004)	Holst 2004
Jimenez-Solem, <i>Dulaglutide, a Long-Acting GLP-1 Analog Fused with an Fc Antibody Fragment for the Potential Treatment of Type 2 Diabetes</i> , 12 CURRENT OP. IN MOLECULAR THERAPEUTICS 790 (2010)	Jimenez-Solem
Kim, <i>Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects with Type 2 Diabetes</i> , 30 DIABETES CARE 1487 (2007) SEMA(JDG)_0002583-2589	Kim

TABLE OF ABBREVIATIONS
(continued)

Full Name of Cited Reference	Abbreviation
Knudsen, <i>GLP-1 Derivatives as Novel Compounds for the Treatment of Type 2 Diabetes: Selection of NN2211 for Clinical Development</i> , 26 DRUGS OF THE FUTURE 677 (2001)	Knudsen 2001
Knudsen, <i>Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes</i> , 47 J. MED. CHEMISTRY 4128 (2004)	Knudsen 2004
Knudsen, <i>Liraglutide, a GLP-1 Analogue to Treat Diabetes in ANALOGUE-BASED DRUG DISCOVERY II</i> (Fischer & Ganellin eds. 2010)	Knudsen 2010a
Knudsen, <i>Liraglutide: The Therapeutic Promise from Animal Models</i> , 64 INT'L J. CLINICAL PRACTICE 4 (2010)	Knudsen 2010b
U.S. Patent No. 6,268,343 SEMA(JDG)_0000487-624	Knudsen patent
Lovshin, <i>Incretin-Based Therapies for Type 2 Diabetes Mellitus</i> , 5 NATURE REV. ENDOCRINOLOGY 262 (2009) SEMA(JDG)_0002250-58	Lovshin
Lund, <i>Emerging GLP-1 Receptor Agonists</i> , 16 EXPERT OP. ON EMERGING DRUGS 607 (2011)	Lund
Madsbad, <i>An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists—Available Efficacy and Safety Data and Perspectives for the Future</i> , 13 DIABETES, OBESITY & METABOLISM 394 (2011) SEMA(JDG)_0002439-52	Madsbad
Marre, <i>GLP-1 Receptor Agonists Today</i> , 93 DIABETES RSCH. & CLINICAL PRAC. 317 (2011)	Marre
Mojsov, <i>Insulinotropin: Glucagon-like Peptide I (7-37) Co-encoded in the Glucagon Gene is a Potent Simulator of Insulin Release in the Perfused Rat Pancreas</i> , 79 J. CLIN. INVEST. 616 (1987)	Mojsov
Monami, <i>Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis</i> , 2012 EXPERIMENTAL DIABETES RSCH. 1 (2012)	Monami

TABLE OF ABBREVIATIONS
(continued)

Full Name of Cited Reference	Abbreviation
NCT00167115, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/show/NCT00167115 (last visited Mar. 15, 2024)	NCT00167115
NCT01933490, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/show/NCT01933490 (last visited Mar. 15, 2024)	NCT01933490
Clinical Trial No. NCT00696657	NCT00696657
Clinical Trial No. NCT00851773	NCT00851773
Nielsen, <i>Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Therapeutic for Improved Glycemic Control of Type 2 Diabetes</i> , 117 REGUL. PEPTIDES 77 (2004)	Nielsen
Novo Nordisk Pipeline – Semaglutide (2010-2011) http://novonordisk.com:80/science/pipeline/rd_pipeline.asp?showid=7 (Internet Archive captures)	Novo Pipeline
Seino, <i>Dose-Dependent Improvement in Glycemia with Once-Daily Liraglutide without Hypoglycemia or Weight Gain: A Double-Blind, Randomized, Controlled Trial in Japanese Patients with Type 2 Diabetes</i> , 81 DIABETES RSCH. & CLINICAL PRACTICE 161 (2008)	Seino
Tamimi, <i>Drug Development: From Concept to Marketing!</i> , 113 NEPHRON CLINICAL PRACTICE c125 (2009)	Tamimi
Tasneem, <i>The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty</i> , 7(3) PLoS ONE 1 (2012)	Tasneem
Victoza, PHYSICIANS' DESK REFERENCE (65th ed. 2011)	Victoza label
Vilsbøll, <i>Glucagon-Like Peptide-1 and Diabetes Treatment</i> , 21 INTERNATIONAL DIABETES MONITOR 1 (2009)	Vilsbøll
Int'l Patent Application Pub. No. WO 03/002136 SEMA(JDG)_0000373-422	WO '136
Int'l Patent Application Pub. No. WO 2011/058193	WO '193
Int'l Patent Application Pub. No. WO 2011/073328	WO '328

TABLE OF ABBREVIATIONS
(continued)

Full Name of Cited Reference	Abbreviation
Int'l Patent Application Pub. No. WO 2011/138421 SEMA(JDG)_0002087-2158	WO '421
Int'l Patent Application Publication No. WO 91/11457	WO '457
Int'l Patent Application Pub. No. WO 2006/097537 SEMA(JDG)_0002453-2528	WO '537
Zarin, <i>The ClinicalTrials.gov Results Database—Update and Key Issues</i> , 364 NEW ENGL. J. MED. 852 (2011)	Zarin

1. My name is John P. Bantle, M.D. I have been retained by Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc., Rio Biopharmaceuticals Inc. and EMS S/A; Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.; and Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (collectively, "defendants"), to provide my expert opinions regarding the invalidity of the asserted claims of U.S. Patent No. 10,335,462 ("462 patent"), which I understand to be claims 1, 3, 4, 5, and 7.

I. QUALIFICATIONS AND BACKGROUND

A. Education and Experience; Prior Testimony

2. I am a medical endocrinologist and Professor Emeritus of Medicine in the Division of Endocrinology and Diabetes, Department of Medicine, at the University of Minnesota. I have substantial experience in clinical research, treatment of patients, and academic publications in the field of the treatment of diabetes and related conditions.

3. I earned a Bachelor of Science degree in 1970 from the University of Minnesota and a Doctor of Medicine degree in 1972 from the University of Minnesota Medical School. I completed an internship at Cleveland Metropolitan General Hospital in 1973; residencies in internal medicine at the Mayo Clinic in Rochester, Minnesota, and Dunedin Public Hospital in

any documents the parties have exchanged. Additionally, I may rely on visual aids and/or demonstrative exhibits that I prepare or have prepared on my behalf based upon my opinions.

I declare that all statements made herein of my knowledge are true, and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Dated: March 19, 2024

By:

John Bantle, MD
Dr. John Bantle